Mercer Global Advisors’s Allogene Therapeutics ALLO Stock Holding History

Mercer Global Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$123K	Buy	58,992 +1,057	+2%	+$2.32K	﹤0.01%	3381
2026 Q1	$141K	Buy	57,935 +28,423	+96%	+$57K	﹤0.01%	2936
2025 Q4	$40.4K	Buy	29,512 +5,514	+23%	+$7.27K	﹤0.01%	2806
2025 Q3	$29.8K	Buy	+23,998	New	+$28.6K	﹤0.01%	2610
2021 Q4	–	Sell	-15,092	Closed	-$388K	–	1796
2021 Q3	$388K	Hold	15,092	–	–	﹤0.01%	1306
2021 Q2	$394K	Hold	15,092	–	–	﹤0.01%	1262
2021 Q1	$533K	Buy	+15,092	New	+$509K	﹤0.01%	1057

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Mercer Global Advisors's ALLO Position: Q2 2026 in Review

Mercer Global Advisors increased its Allogene Therapeutics (ALLO) stake by 1.8% in Q2 2026, buying an estimated $2.32K and bringing the position to 58,992 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #3381.

Mercer Global Advisors first reported a position in ALLO in Q1 2021 and has held it in 7 quarters since. The position peaked at $533K in Q1 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Mercer Global Advisors held 58,992 shares of Allogene Therapeutics worth $123K as of Q2 2026.
Mercer Global Advisors bought 1,057 Allogene Therapeutics shares in Q2 2026, an estimated $2.32K.
Allogene Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3381 holding.
Mercer Global Advisors first reported a position in Allogene Therapeutics in Q1 2021 and has held it in 7 quarters since.
Mercer Global Advisors's Allogene Therapeutics position peaked at $533K in Q1 2021.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.